Homocystinuria https://greenmedinfo.com/taxonomy/term/1549/all en Cystathionine beta-Synthase Deficiency Disease https://greenmedinfo.com/disease/cystathionine-beta-synthase-deficiency-disease <div class="field field-image"> <div class="field-items"> <div class="field-item odd"> <img class="imagefield imagefield-field_image" width="450" height="338" alt="" src="//cdn.greenmedinfo.com/sites/default/files/Genes_106.jpg?1473458169" /> </div> </div> </div> <div class="field field-copyright"> <div class="field-items"> <div class="field-item odd"> Copyright: &lt;a href=&#039;http://www.123rf.com/profile_nobeastsofierce&#039;&gt;nobeastsofierce / 123RF Stock Photo&lt;/a&gt; </div> </div> </div> <fieldset class="fieldgroup group-facebook-like-info"><legend>Facebook Like Info</legend><div class="field field-facebook-total-count"> <div class="field-items"> <div class="field-item odd"> 0 </div> </div> </div> </fieldset> Homocystinuria Tue, 14 Apr 2009 07:16:18 +0000 greenmedinfo 19591 at https://greenmedinfo.com Health functionalities of betaine in patients with homocystinuria. https://greenmedinfo.com/article/health-functionalities-betaine-patients-homocystinuria PMID:  Front Nutr. 2021 ;8:690359. Epub 2021 Sep 9. PMID: 34568401 Abstract Title:  Health Functionalities of Betaine in Patients With Homocystinuria. Abstract:  Homocystinuria is a medical condition that can have widespread and harmful effects on multiple organ systems within the body. This disease is caused by a deficiency in one of the enzymes involved in the methionine metabolism pathway. One example would be a deficiency in cystathionine-β-synthase (CBS), which is seen in classical homocystinuria. A deficiency in CBS can lead to elevated levels of homocysteine (HCY) and possible depletion of methionine and/or cysteine. There are several different treatment options for patients with this condition, one of which is the administrationof the drug betaine. Here we review the use of betaine to decrease these elevated levels of homocysteine back to within normal ranges. Published literature indicates that the use of this choline derivative is most beneficial to patients who are either not compliant with the recommended low methionine and low protein diet or wish to consume a less restricted diet. <p><a href="https://greenmedinfo.com/article/health-functionalities-betaine-patients-homocystinuria" target="_blank">read more</a></p> https://greenmedinfo.com/article/health-functionalities-betaine-patients-homocystinuria#comments Betaine Homocystinuria Review Sat, 11 Dec 2021 20:23:05 +0000 greenmedinfo 250038 at https://greenmedinfo.com Homocysteine-lowering therapy may prevent bone loss in Parkinson's disease patients taking levodopa. https://greenmedinfo.com/article/homocysteine-lowering-therapy-may-prevent-bone-loss-parkinsons-disease-patient PMID:  Mov Disord. 2010 Feb 15;25(3):332-40. PMID: 19938151 Abstract Title:  Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson&#039;s disease. Abstract:  We investigated whether homocysteine (Hcy)- lowering therapy or an antioxidant prevented bone loss in Parkinson&#039;s disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 microg vitamin B(12) daily), alpha-lipoic acid (alpha-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%) than control (P = 0.005-0.023). BMD changes in the alpha-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6%) were significantly greater in the alpha-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2% +/- 13.4% in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 +/- 0.024 ng/mL) than control group (0.628 +/- 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa. https://greenmedinfo.com/article/homocysteine-lowering-therapy-may-prevent-bone-loss-parkinsons-disease-patient#comments Alpha-Lipoic Acid Homocystinuria Parkinson's Disease Vitamin B-12 Antioxidants Diseases that are Linked Human Study Tue, 23 Nov 2010 19:14:07 +0000 greenmedinfo 58968 at https://greenmedinfo.com